Skip to main content
×
Home

Fragment-based approaches to TB drugs

  • CHIARA MARCHETTI (a1), DANIEL S. H. CHAN (a1), ANTHONY G. COYNE (a1) and CHRIS ABELL (a1)
Summary
SUMMARY

Tuberculosis is an infectious disease associated with significant mortality and morbidity worldwide, particularly in developing countries. The rise of antibiotic resistance in Mycobacterium tuberculosis (Mtb) urgently demands the development of new drug leads to tackle resistant strains. Fragment-based methods have recently emerged at the forefront of pharmaceutical development as a means to generate more effective lead structures, via the identification of fragment molecules that form weak but high quality interactions with the target biomolecule and subsequent fragment optimization. This review highlights a number of novel inhibitors of Mtb targets that have been developed through fragment-based approaches in recent years.

Copyright
Corresponding author
*Corresponding author: Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge CB2 1EW, UK. E-mail: ca26@cam.ac.uk; agc40@cam.ac.uk
References
Hide All
Barr A. J., Ugochukwu E., Lee W. H., King O. N., Filippakopoulos P., Alfano I., Savitsky P., Burgess-Brown N. A., Müller S. and Knapp S. (2009). Large-scale structural analysis of the classical human protein tyrosine phosphatome. Cell 136, 352363.
Belin P., Le Du M. H., Fielding A., Lequin O., Jacquet M., Charbonnier J. B. Lecoq A., Thai R., Courçon M., Masson C., Dugave C., Genet R., Pernodet J. L. and Gondry M. (2009). Identification and structural basis of the reaction catalyzed by CYP121, an essential cytochrome P450 in Mycobacterium tuberculosis . Proceedings of the National Academy of Sciences of the United States of America 106(18), 74267431.
Belisle J. T., Vissa V. D., Sievert T., Takayama K., Brennan P. J. and Besra G. S. (1997). Role of the major antigen of Mycobacterium tuberculosis in cell wall biogenesis. Science 276, 14201422.
Cole S. T., Brosch R., Parkhill J., Garnier T., Churcher C., Harris D., Gordon S. V., Eiglmeier K., Gas S., Barry C. E., Tekaia F., Badcock K., Basham D., Brown D., Chillingworth T., Connor R., Davies R., Devlin K., Feltwell T., Gentles S., Hamlin N., Holroyd S., Hornsby T., Jagels K., Krogh A., McLean J., Moule S., Murphy L., Oliver K., Osborne J. et al. (1998). Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393, 537544.
Congreve M., Chessari G., Tisi D. and Woodhead A. J. (2008). Recent developments in fragment based drug discovery. Journal of Medicinal Chemistry 51, 36613680.
Dai R., Wilson D. J., Geders T. W., Aldrich C. C. and Finzel B. C. (2014). Inhibition of Mycobacterium tuberculosis transaminase BioA by Aryl Hydrazines and Hydrazides. ChemBioChem 15, 575586.
Dover L. G., Corsino P. E., Daniels I. R., Cocklin I. R., Tatituri V., Besra G. S. and Fütterer K. (2004). Crystal Structure of the TetR/CamR Family Repressor Mycobacterium tuberculosis EthR Implicated in Ethionamide Resistance. Journal of Molecular Biology 340, 10951105.
Engohang-Ndong J., Baillat D., Aumercier M., Bellefontaine F., Besra G. S., Locht C. and Baulard A. R. (2004). EthR, a repressor of the TetR/CamR family implicated in ethionamide resistance in mycobacteria, octamerizes cooperatively on its operator. Molecular Microbiology 51, 175188.
Flipo M., Desroses M., Lecat-Guillet N., Dirié B., Carette X., Leroux F., Piveteau C., Demirkaya F., Lens Z., Rucktooa P., Villeret V., Christophe T., Jeon H. K., Locht C., Brodin P., Déprez B., Baulard A. R. and Willand N. (2011). Ethionamide boosters: synthesis, biological activity, and structure–activity relationships of a series of 1,2,4-Oxadiazole EthR inhibitors. Journal of Medicinal Chemistry 54, 29943010.
Flipo M., Desroses M., Lecat-Guillet N., Villemagne B., Blondiaux N., Leroux F., Piveteau C., Mathys V., Flament M. P., Siepmann J., Villeret V., Wohlkönig A., Wintjens R., Soror S. H., Christophe T., Jeon H. K., Locht C., Brodin P., Déprez B., Baulard A. R. and Willand N. (2012 a). Ethionamide boosters. 2. combining bioisosteric replacement and structure-based drug design to solve pharmacokinetic issues in a series of potent 1,2,4-Oxadiazole EthR inhibitors. Journal of Medicinal Chemistry 55, 6883.
Flipo M., Willand N., Lecat-Guillet N., Hounsou C., Desroses M., Leroux F., Lens Z., Villeret V., Wohlkönig A., Wintjens R., Christophe T., Kyoung Jeon H., Locht C., Brodin P., Baulard A. R. and Déprez B. (2012 b). Discovery of novel N-phenylphenoxyacetamide derivatives as EthR inhibitors and ethionamide boosters by combining high-throughput screening and synthesis. Journal of Medicinal Chemistry 55, 63916402.
Frénois F., Engohang-Ndong J., Locht C., Baulard A. R. and Villeret V. (2004). Structure of EthR in a ligand bound conformation reveals therapeutic perspectives against tuberculosis. Molecular Cell 16, 301307.
Hotta K., Kitahara T. and Okami Y. (1975). Studies on the mode of action of amiclenomycin. Journal of Antibiotics 28, 222228.
Hudson S. A., McLean K. J., Munro A. W. and Abell C. (2012 a). Mycobacterium tuberculosis cytochrome P450 enzymes: a cohort of novel TB drug targets. Biochemical Society Transactions 40(3), 573579.
Hudson S. A., McLean K. J., Surade S., Yang Y. Q., Leys D., Ciulli A., Munro A. W. and Abell A. (2012 b). Application of fragment screening and merging to the discovery of inhibitors of the Mycobacterium tuberculosis cytochrome P450 CYP121. Angewandte Chemie International Edition 51, 93119316.
Hudson S. A., Surade S., Coyne A. G., McLean K. J., Leys D., Munro A. W. and Abell C. (2013). Overcoming the limitations of fragment merging: rescuing a strained merged fragment series targeting Mycobacterium tuberculosis CYP121. ChemMedChem 8, 14511456.
Hung A. W., Silvestre H. L., Wen S., Ciulli A., Blundell T. L. and Abell C. (2009). Application of fragment growing and fragment linking to the discovery of inhibitors of Mycobacterium tuberculosis pantothenate synthetase. Angewandte Chemie International Edition 48, 84528456.
Hung A. W., Silvestre H. L., Wen S., George G. P., Boland J., Blundell T. L., Ciulli A. and Abell C. (2016). Optimization of inhibitors of Mycobacterium tuberculosis pantothenate synthetase based on group efficiency analysis. ChemMedChem 11, 3842.
Jackson M., Raynaud C., Lanéelle M. A., Guilhot C., Laurent-Winter C., Ensergueix D., Gicquel B. and Daffé M. (1999). Inactivation of the antigen 85C gene profoundly affects the mycolate content and alters the permeability of the Mycobacterium tuberculosis cell envelope. Molecular Microbiology 31, 15731587.
Kavanagh M. E., Coyne A. G., McLean K. J., James G. G., Levy C. W., Marino L. B., de Carvalho L. P. S., Chan D. S. H., Hudson S. A., Surade S., Leys D., Munro A. W. and Abell C. (2016). Fragment-based approaches to the development of Mycobacterium tuberculosis CYP121 inhibitors. Journal of Medicinal Chemistry 59, 32723302.
Koul A., Arnoult E., Lounis N., Guillemont J. and Andries K. (2011). The challenge for new drug discovery for tuberculosis. Nature 469, 483490.
Leys D., Mowat C. G., McLean K. J., Richmond A., Chapman S. K., Walkinshaw M. D. and Munro A. W. (2003). Atomic structure of Mycobacterium tuberculosis CYP121 to 1·06 A reveals novel features of cytochrome P450. Journal of Biological Chemistry 278, 51415147.
Mascarello A., Mori M., Chiaradia-Delatorre L. D., Menegatti A. C., Delle Monache F., Ferrari F., Yunes R. A., Nunes R. J., Terenzi H., Botta B. and Botta M. (2013). Discovery of Mycobacterium tuberculosis protein tyrosine phosphatase B (PtpB) inhibitors from natural products. PLoS ONE 8, e77081.
Mashalidis E., Śledź P., Lang S. and Abell C. (2013). A three-stage biophysical screening cascade for fragment-based drug discovery. Nature Protocols 8, 23092324.
McLean K. J., Carroll P., Lewis D. G., Dunford A. J., Seward H. E., Neeli R., Cheesman M. R., Marsollier L., Douglas P., Smith W. E., Rosenkrands I., Cole S. T., Leys D., Parish T. and Munro A. W. (2008). Characterization of active site structure in CYP121. A cytochrome P450 essential for viability of Mycobacterium tuberculosis H37Rv. Journal of Biological Chemistry 283, 3340633416.
Murray C. W. and Blundell T. L. (2010). Structural biology in fragment-based drug design. Current Opinion in Structural Biology 20, 497507.
Nikiforov P. O., Surade S., Blaszczyk M., Delorme V., Brodin P., Baulard A. R., Blundell T. L. and Abell C. (2016). A fragment merging approach towards the development of small molecule inhibitors of Mycobacterium tuberculosis EthR for use as ethionamide boosters. Organic and Biomolecular Chemistry 14, 23182326.
Park S. W., Klotzsche M., Wilson D. J., Boshoff H. I., Eoh H., Manjunatha U., Blumenthal A., Rhee K., Barry C. E. III, Aldrich C. C., Ehrt S. and Schnappinger D. (2011). Evaluating the sensitivity of Mycobacterium tuberculosis to biotin deprtication using regulated gene expression. PLoS Pathogens 7, e1002264, 1–0.
Rawls K. A., Lang T. P., Takeuchi J., Imamura S., Baguley T. D., Grundner C., Alber T. and Ellman J. A. (2009). Fragment-based discovery of selective inhibitors of the Mycobacterium tuberculosis protein tyrosine phosphatase PtpA. Bioorganic and Medicinal Chemistry Letters 19, 68516854.
Sambandamurthy V. K., Wang X., Chen B., Russell R. G., Derrick S., Collins F. M., Morris S. L. and Jacobs W. R. (2002). A pantothenate auxotroph of Mycobacterium tuberculosis is highly attenuated and protects mice against tuberculosis. Nature Medicine 8, 11711174.
Scheich C., Puetter V. and Schade M. (2010). Novel small molecule inhibitors of MDR Mycobacterium tuberculosis by NMR fragment screening of antigen 85 °C. Journal of Medicinal Chemistry 53, 83628367.
Schmidt M. F., Groves M. R. and Rademann J. (2011). Dynamic substrate enhancement for the identification of specific, second-site-binding fragments targeting a set of protein tyrosine phosphatases. ChemBioChem 12, 26402646.
Scott D. E., Coyne A. G., Hudson S. A. and Abell C. (2012). Fragment based approaches in drug discovery and chemical biology. Biochemistry 51, 49905003.
Shi C. and Aldrich C. C. (2012). Design and synthesis of potential mechanism-based inhibitors of the aminotransferase BioA involved in biotin biosynthesis. Journal of Organic Chemistry 77, 60516058.
Silvestre H. L., Blundell T. L., Abell C. and Ciulli A. (2013). Integrated biophysical approach to fragment screening and validation for fragment-based lead discovery. Proceedings of the National Academy of Sciences of the United States of America 110, 1298412989.
Singh R., Rao V., Shakila H., Gupta R., Khera A., Dhar N., Singh A., Koul A., Singh Y., Naseema M., Narayanan P. R., Paramasivan C. N., Ramanathan V. D. and Tyagi A. K. (2003). Disruption of mptpB impairs the ability of Mycobacterium tuberculosis to survive in guinea pigs. Molecular Microbiology 50, 751762.
Soellner M. B., Rawls K. A., Grundner C., Alber T. and Ellman J. A. (2007). Fragment-based substrate activity screening method for the identification of potent inhibitors of the Mycobacterium tuberculosis phosphatase PtpB. Journal of the American Chemical Society 129, 96139615.
Spry C., Kirk K. and Saliba K. J. (2008). Coenzyme A biosynthesis: an antimicrobial drug target. FEMS Microbiology Reviews 32, 56106.
Surade S., Ty N., Hengrung N., Lechartier B., Cole S. T., Abell C. and Blundell T. L. (2014). A structure-guided fragment-based approach for the discovery of allosteric inhibitors targeting the lipophilic binding site of transcription factor EthR. Biochemical Journal 458, 387394.
Tan L. P., Wu H., Yang P. Y., Kalesh K. A., Zhang X., Hu M., Srinivasan R. and Yao S. Q. (2009). High-throughput discovery of Mycobacterium tuberculosis protein tyrosine phosphatase B (MptpB) inhibitors using click chemistry. Organic Letters 11, 51025105.
Tonks N. K. (2006). Protein tyrosine phosphatases: from genes, to function, to disease. Nature Reviews Molecular Cell Biology 7, 833846.
Vannelli T. A., Dykman A. and Ortiz de Montellano P. R. (2002). The antituberculosis drug ethionamide is activated by a flavoprotein monooxygenase. Journal of Biological Chemistry 77, 1282412829.
Villemagne B., Flipo M., Blondiaux N., Crauste C., Malaquin S., Leroux F., Piveteau C., Villeret V., Brodin P., Villoutreix B. O., Sperandio O., Soror S. H., Wohlkönig A., Wintjens R., Deprez B., Baulard A. R. and Willand N. (2014). Ligand efficiency driven design of new inhibitors of Mycobacterium tuberculosis transcriptional repressor EthR using fragment growing, merging, and linking approaches. Journal of Medicinal Chemistry 57, 48764888.
Wang S. and Eisenberg D. (2003). Crystal structures of a pantothenate synthetase from M. tuberculosis and its complexes with substrates and a reaction intermediate. Protein Science 12, 10971108.
Webb M. E., Smith A. G. and Abell C. (2002). Biosynthesis of pantothenate. Natural Product Reports 21, 695721.
Willand N., Dirié B., Carette X., Bifani P., Singhal A., Desroses M., Leroux F., Willery E., Mathys V., Déprez-Poulain R., Delcroix G., Frénois F., Aumercier M., Locht C., Villeret V., Déprez B. and Baulard A. R. (2009). Synthetic EthR inhibitors boost antituberculous activity of ethionamide. Nature Medicine 15, 537544.
Woong Park S., Klotzsche M., Wilson D. J., Boshoff H. I., Eoh H., Manjunatha U., Blumenthal A., Rhee K., Barry C. E. III, Aldrich C. C., Ehrt S. and Schnappinger D. (2011). Evaluating the sensitivity of Mycobacterium tuberculosis to biotin deprivation using regulated gene expression. PLoS Pathogens 7, e1002264.
World Health Organisation (2015). Global tuberculosis report, Geneva; (http://apps.who.int/iris/bitstream/10665/191102/1/9789241565059_eng.pdf?ua=1 (accessed October 2016).
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Parasitology
  • ISSN: 0031-1820
  • EISSN: 1469-8161
  • URL: /core/journals/parasitology
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Keywords:

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 33
Total number of PDF views: 180 *
Loading metrics...

Abstract views

Total abstract views: 548 *
Loading metrics...

* Views captured on Cambridge Core between 2nd November 2016 - 20th November 2017. This data will be updated every 24 hours.